Regenxbio (RGNX) Common Equity (2014 - 2026)
Regenxbio (RGNX) posted quarterly Common Equity of $102.7 million for Q4 2025, down 60.43% year-over-year from $259.7 million in Q4 2024, and down 36.37% quarter-over-quarter from $161.5 million in Q3 2025.
Regenxbio (RGNX) Common Equity (2014 - 2026) Analysis & Trends
Regenxbio's Common Equity history runs 12 years deep, the most recent figure standing at $102.7 million for Q4 2025.
- In Q4 2025, Common Equity fell 60.43% year-over-year to $102.7 million; the TTM figure through Dec 2025 stood at $102.7 million (down 60.43% YoY), while the FY2025 annual figure was $102.7 million, down 60.43% from the prior year.
- Common Equity for Q4 2025 stood at $102.7 million, down from $161.5 million in the prior quarter.
- The five-year high for Common Equity was $764.3 million in Q4 2021, with the low at $102.7 million in Q4 2025.
- The 5-year median for Common Equity is $398.3 million (2023), against an average of $414.3 million.
- The sharpest annual moves came in 2021 and 2025: Common Equity surged 102.33% in 2021, then sank 60.43% in 2025.
- Regenxbio's Common Equity stood at $764.3 million in 2021, then slumped by 32.46% to $516.2 million in 2022, then plunged by 39.61% to $311.7 million in 2023, then declined by 16.71% to $259.7 million in 2024, then tumbled by 60.43% to $102.7 million in 2025.
- Business Quant data shows RGNX's Common Equity at $102.7 million in Q4 2025, $161.5 million in Q3 2025, and $213.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 71.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.77 Mn |
| Dec 31, 2025 | 102.73 Mn |
| Sep 30, 2025 | 161.45 Mn |
| Jun 30, 2025 | 213.68 Mn |
| Mar 31, 2025 | 274.20 Mn |
| Dec 31, 2024 | 259.65 Mn |
| Sep 30, 2024 | 301.42 Mn |
| Jun 30, 2024 | 348.27 Mn |
| Mar 31, 2024 | 390.67 Mn |
| Dec 31, 2023 | 311.74 Mn |
| Sep 30, 2023 | 363.10 Mn |
| Jun 30, 2023 | 405.86 Mn |
| Mar 31, 2023 | 465.14 Mn |
| Dec 31, 2022 | 516.20 Mn |
| Sep 30, 2022 | 563.82 Mn |
| Jun 30, 2022 | 630.52 Mn |
| Mar 31, 2022 | 689.67 Mn |
| Dec 31, 2021 | 764.30 Mn |
| Sep 30, 2021 | 461.41 Mn |
| Jun 30, 2021 | 507.25 Mn |